EP1987068A4 - Oligosaccharide modification and labeling of proteins - Google Patents

Oligosaccharide modification and labeling of proteins

Info

Publication number
EP1987068A4
EP1987068A4 EP07756886A EP07756886A EP1987068A4 EP 1987068 A4 EP1987068 A4 EP 1987068A4 EP 07756886 A EP07756886 A EP 07756886A EP 07756886 A EP07756886 A EP 07756886A EP 1987068 A4 EP1987068 A4 EP 1987068A4
Authority
EP
European Patent Office
Prior art keywords
labeling
proteins
oligosaccharide modification
oligosaccharide
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07756886A
Other languages
German (de)
French (fr)
Other versions
EP1987068A1 (en
EP1987068B1 (en
Inventor
Brian Agnew
Schyler B Corry
Kyle R Gee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38440198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1987068(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Priority to EP22156335.6A priority Critical patent/EP4092418A1/en
Priority to EP18187681.4A priority patent/EP3438131B1/en
Priority to DK18187681.4T priority patent/DK3438131T3/en
Publication of EP1987068A1 publication Critical patent/EP1987068A1/en
Publication of EP1987068A4 publication Critical patent/EP1987068A4/en
Application granted granted Critical
Publication of EP1987068B1 publication Critical patent/EP1987068B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP07756886.3A 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins Active EP1987068B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22156335.6A EP4092418A1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins
EP18187681.4A EP3438131B1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins
DK18187681.4T DK3438131T3 (en) 2006-02-10 2007-02-12 OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77222106P 2006-02-10 2006-02-10
US80464006P 2006-06-13 2006-06-13
PCT/US2007/062006 WO2007095506A1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP22156335.6A Division EP4092418A1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins
EP18187681.4A Division EP3438131B1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins

Publications (3)

Publication Number Publication Date
EP1987068A1 EP1987068A1 (en) 2008-11-05
EP1987068A4 true EP1987068A4 (en) 2012-12-26
EP1987068B1 EP1987068B1 (en) 2018-08-08

Family

ID=38440198

Family Applications (7)

Application Number Title Priority Date Filing Date
EP18187681.4A Active EP3438131B1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins
EP13162096.5A Active EP2623609B1 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP20130162103 Not-in-force EP2623610B1 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP07825657.5A Active EP1991273B2 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP13162088.2A Active EP2623986B1 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP07756886.3A Active EP1987068B1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins
EP22156335.6A Pending EP4092418A1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins

Family Applications Before (5)

Application Number Title Priority Date Filing Date
EP18187681.4A Active EP3438131B1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins
EP13162096.5A Active EP2623609B1 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP20130162103 Not-in-force EP2623610B1 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP07825657.5A Active EP1991273B2 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins
EP13162088.2A Active EP2623986B1 (en) 2006-02-10 2007-02-12 Labeling and detection of post translationally modified proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22156335.6A Pending EP4092418A1 (en) 2006-02-10 2007-02-12 Oligosaccharide modification and labeling of proteins

Country Status (5)

Country Link
US (10) US20070249014A1 (en)
EP (7) EP3438131B1 (en)
JP (4) JP2009528988A (en)
DK (3) DK1991273T4 (en)
WO (2) WO2007095506A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2816182C2 (en) * 2021-04-12 2024-03-26 Академиа Синика Advanced coronavirus vaccine

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3438131B1 (en) * 2006-02-10 2022-03-16 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
CA2644917A1 (en) * 2006-03-15 2007-09-20 Trustees Of Tufts College Fluorinated carbohydrates and their use in tumor visualization, tissue engineering, and cancer chemotherapy
US8034396B2 (en) * 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
CA2723197C (en) * 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
JP5569768B2 (en) * 2008-12-02 2014-08-13 国立大学法人九州大学 Nucleoside triphosphate derivative, nucleic acid probe, multi-labeled nucleic acid probe, and method for detecting target nucleic acid
BR122020010601B8 (en) 2008-12-16 2021-07-27 Genzyme Corp protein-oligosaccharide conjugates, their uses, and pharmaceutical compositions
WO2010091142A1 (en) * 2009-02-04 2010-08-12 President And Fellows Of Harvard College Compositions and methods for labeling and imaging phospholipids
CA2752241A1 (en) * 2009-02-14 2010-08-19 Genentech, Inc. Methods for the detection of fatty-acylated proteins
AU2010215194A1 (en) 2009-02-21 2011-10-13 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
AU2010215196B2 (en) 2009-02-21 2015-04-16 Covidien Lp Crosslinked fibers and method of making same by extrusion
AU2010215931A1 (en) 2009-02-21 2011-10-13 Covidien Lp Medical devices having activated surfaces
WO2010095045A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
EP2398943B1 (en) 2009-02-21 2013-04-17 Sofradim Production Crosslinked fibers and method of making same using uv radiation
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
WO2010095053A2 (en) 2009-02-21 2010-08-26 Sofradim Production Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
AU2010215936B2 (en) 2009-02-21 2015-03-05 Covidien Lp Medical devices having activated surfaces
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8877170B2 (en) * 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
EP2253635B1 (en) 2009-04-28 2014-03-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel hydrophilic and lipophilic rhodamines for labelling and imaging
WO2010149190A1 (en) * 2009-06-26 2010-12-29 Max-Planck-Gesellschaft Zur Novel fluorinated rhodamines as photostable fluorescent dyes for labelling and imaging techniques
US8440905B2 (en) * 2009-09-25 2013-05-14 Robert J. LeSuer Copper complex dye sensitized solar cell
EP3483610A1 (en) 2009-11-09 2019-05-15 University Of Washington Center For Commercialization Functionalized chromophoric polymer dots and bioconjugates thereof
US20110108411A1 (en) * 2009-11-11 2011-05-12 Popik Vladimir V Methods for labeling a substrate using a hetero-diels-alder reaction
US9090542B2 (en) * 2009-11-11 2015-07-28 University Of Georgia Research Foundation, Inc. Methods for labeling a substrate using a hetero-diels-alder reaction
US20110129834A1 (en) * 2009-11-24 2011-06-02 Life Technologies Corporation Selective amplification of polynucleotide sequences
US9272074B2 (en) * 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
EP2550031B1 (en) 2010-03-25 2015-08-19 Sofradim Production Medical devices incorporating functional adhesives
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
CA2804251A1 (en) 2010-07-01 2012-01-05 Sofradim Production Medical device with predefined activated cellular integration
AU2011284449B2 (en) 2010-07-27 2015-07-23 Sofradim Production Polymeric fibers having tissue reactive members
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
CN103237546B (en) 2010-07-28 2016-06-08 生命科技公司 The antiviral compound that contains azide
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
CA2814790C (en) 2010-10-18 2019-11-19 University of Washington Center for Commercialization Chromophoric polymer dots
AU2012264696A1 (en) 2011-05-31 2013-12-12 Probiogen Ag Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
US9164086B2 (en) 2011-10-18 2015-10-20 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Fluorescent dyes with phosphorylated hydroxymethyl groups and their use in light microscopy and imaging techniques
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
US10150841B2 (en) 2011-12-30 2018-12-11 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
WO2013112778A1 (en) * 2012-01-26 2013-08-01 Life Technologies Corporation Methods for increasing the infectivity of viruses
EP2809510B1 (en) 2012-02-03 2021-03-31 University of Washington through its Center for Commercialization Polyelectrolyte-coated polymer dots and related methods
ES2678211T3 (en) 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Signaling conjugates and use procedures
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
RS64329B1 (en) * 2012-10-23 2023-08-31 Synaffix Bv Modified antibody, antibody-conjugate and process for the preparation thereof
WO2014066733A2 (en) * 2012-10-25 2014-05-01 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
CN104007091A (en) * 2013-02-26 2014-08-27 中国科学院天津工业生物技术研究所 High-throughput detection system for microbe based on droplet microfluidic chip
JP6587605B2 (en) 2013-03-14 2019-10-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション Polymer dot compositions and related methods
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
SG10201710033PA (en) 2013-06-04 2018-01-30 Tribiotica Llc Methods and compositions for templated assembly of nucleic acid specific heterocompounds
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057064A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
CN105829543B (en) * 2013-10-14 2021-06-01 西纳福克斯股份有限公司 Glycosylated antibodies, antibody-conjugates and methods of making the same
WO2015057063A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
CN103604791B (en) * 2013-11-29 2016-01-20 广西师范大学 A kind of fluorescence spectrum method measuring azides ion
EP3097080A1 (en) 2014-01-24 2016-11-30 SynAffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
CN106660967A (en) 2014-01-24 2017-05-10 西纳福克斯股份有限公司 Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
US20170009266A1 (en) 2014-01-24 2017-01-12 Synaffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
JP5847213B2 (en) * 2014-02-06 2016-01-20 ホーユー株式会社 Two-dimensional electrophoresis method
KR20160143774A (en) 2014-04-08 2016-12-14 고쿠리츠다이가쿠호징 히로사키다이가쿠 Novel glucose derivative, and cell imaging method and imaging agent using said derivative
US10905678B2 (en) 2014-04-08 2021-02-02 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
EP3177633B1 (en) 2014-08-04 2022-07-20 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016089958A1 (en) 2014-12-02 2016-06-09 Tribiotica Llc Methods and kits for theranostic applications
CN104761726B (en) * 2015-01-08 2020-05-22 湖南工业大学 Method for regulating and controlling ordered pore diameter of ethyl cellulose grafted polystyrene copolymer material based on main chain length
ES2659816T3 (en) 2015-04-23 2018-03-19 Synaffix B.V. Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from one (1,4) -n-acetylgalactosaminyltransferase
CA3003627C (en) * 2015-11-10 2023-11-21 Eth Zurich Tri-functional crosslinking reagents
EP3377093B1 (en) 2015-11-19 2022-07-13 Takeda Pharmaceutical Company Limited Recombinant human c1 esterase inhibitor and uses thereof
CN105399639A (en) * 2015-12-14 2016-03-16 天津科技大学 Tyramine artificial antigen and antibody, and preparation methods and application thereof
WO2017137459A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Enzymes for trimming of glycoproteins
JP2019507741A (en) 2016-02-08 2019-03-22 シンアフィックス ビー．ブイ． Bioconjugates comprising sulfamide linkers for use in therapy
EP3413922A1 (en) 2016-02-08 2018-12-19 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
CN109069658B (en) * 2016-02-08 2022-10-14 西纳福克斯股份有限公司 Antibody-conjugates with improved therapeutic index for targeting HER2 tumors and methods for improving the therapeutic index of antibody-conjugates
CA3027505A1 (en) * 2016-06-15 2017-12-21 The General Hospital Corporation Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions
EP3472210A1 (en) * 2016-06-17 2019-04-24 Life Technologies Corporation Site-specific crosslinking of antibodies
US10723760B2 (en) * 2016-09-02 2020-07-28 Korea Advanced Institute Of Science And Technology Method for preparing site-specifically modified protein based on novel carbon-carbon bond formation
WO2018044130A1 (en) * 2016-09-02 2018-03-08 한국과학기술원 Novel method for producing protein having a carbon-carbon bond-based site-specific modification
CN110121559A (en) 2016-11-21 2019-08-13 特里比奥迪卡有限责任公司 The method of the orientation assembled folding or dimerization of protein is carried out by templating group reaction cartridge
US11186839B2 (en) 2016-11-21 2021-11-30 Tribiotica Llc Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations
TWI673363B (en) 2016-12-29 2019-10-01 財團法人生物技術開發中心 Processes for preparing glycoprotein-drug conjugates
CN108264372B (en) * 2016-12-30 2021-08-24 四川大学 High-strength low-heat-conductivity A-grade non-combustible aerogel foam and preparation and application thereof
CN108728397B (en) * 2017-04-17 2022-05-20 中国科学院微生物研究所 Method for marking insect protein or foreign protein expressed by insect expression system
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
US20180372751A1 (en) * 2017-06-23 2018-12-27 The Scripps Research Institute Lysine reactive probes and uses thereof
CN107486270B (en) * 2017-08-08 2020-10-23 上海格荣生物科技有限公司 Preparation method of microarray chip based on ball-brush double-layer nanostructure substrate
CN110093303A (en) * 2018-01-29 2019-08-06 浙江千禾生物科技有限公司 A kind of semisolid culturemedium and its application
AU2019291176A1 (en) 2018-06-19 2020-12-10 Glykos Finland Oy Conjugate
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210081324A (en) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. Muscle targeting complexes and their use for treating facioscapulohumeral muscular dystrophy
CN109316463B (en) * 2018-08-03 2021-03-19 暨南大学 Composite nanoparticle and preparation method and application thereof
CN113260384A (en) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 Antibody conjugates for targeting TROP-2 expressing tumors
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
US20220146516A1 (en) * 2019-02-20 2022-05-12 Diamidex Methods for labeling eukaryotic cells from a multicellular organism as well as for treating and/or diagnosing a cancer using modified monosaccharide compounds
WO2020228734A1 (en) * 2019-05-13 2020-11-19 Shanghai Polaris Biology Co., Ltd. A tag for labeling biomolecules
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
TW202334429A (en) 2021-10-01 2023-09-01 中央研究院 Antibody specific to spike protein of sars-cov-2 and uses thereof
GB202116442D0 (en) * 2021-11-15 2021-12-29 Actome Gmbh High-efficacy labeling of antibodies with oligonucleotide labels
WO2023180485A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
WO2023180490A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023180484A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing ptk7
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
EP4285934A1 (en) 2022-05-30 2023-12-06 CER Groupe Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
CN115656350A (en) * 2022-09-05 2023-01-31 华熙生物科技股份有限公司 Method for determining modification site and crosslinking mode of crosslinked hyaluronic acid
CN115951070A (en) * 2023-01-19 2023-04-11 北京青莲百奥生物科技有限公司 Method for detecting protein in sample

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130235A1 (en) * 2003-11-18 2005-06-16 Linda Hsieh-Wilson Method and compositions for the detection of protein glycosylation

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527027A (en) * 1894-10-02 Method of and apparatus for producing letters or characters in bread
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
JPS6033479B2 (en) 1980-07-30 1985-08-02 協和醗酵工業株式会社 Method for quantifying hydrogen peroxide
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4520110A (en) 1981-10-06 1985-05-28 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
US4859582A (en) 1981-10-06 1989-08-22 The Board Of Trustees Of The Leland Stanford Jr. University Fluorescent conjugates for analysis of molecules and cells
US5055556A (en) 1981-10-06 1991-10-08 The Board Of Trustees Of The Leland Stanford Jr. Univ. Fluorescent conjugates for analysis of molecules and cells
US4542104A (en) 1983-04-06 1985-09-17 The Board Of Trustees Of The Leland Stanford Jr. Univ. Phycobiliprotein fluorescent conjugates
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4603209A (en) 1984-09-07 1986-07-29 The Regents Of The University Of California Fluorescent indicator dyes for calcium ions
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
FR2574415B1 (en) * 1984-12-11 1987-05-29 Rhone Poulenc Spec Chim LOW TEMPERATURE FLEXIBLE TECHNICAL COPOLYETHERAMIDES
US4714763A (en) * 1985-07-11 1987-12-22 Viomedics Inc. Novel oxazine-ureas and thiazine urea chromophors as fluorescent labels
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US4810636A (en) * 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4945171A (en) 1987-08-10 1990-07-31 Molecular Probes, Inc. Xanthene dyes having a fused (C) benzo ring
US4849362A (en) 1988-05-19 1989-07-18 Smithkline Beckman Corporation Fluorescent intracellular calcium indicators
US5196306A (en) 1989-03-29 1993-03-23 E. I. Du Pont De Nemours And Company Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system
US4981977A (en) 1989-06-09 1991-01-01 Carnegie-Mellon University Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups
US5279954A (en) * 1989-06-30 1994-01-18 Board Of Regents Of The University Of Nebraska And Bionebraska Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins
US5132432A (en) * 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5202422A (en) * 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5501980A (en) 1994-05-20 1996-03-26 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
US5723289A (en) 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5208148A (en) 1990-12-07 1993-05-04 Molecular Probes, Inc. Lipophilic fluorescent glycosidase substrates
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
WO1993020096A1 (en) 1991-05-08 1993-10-14 Stratagene Oligonucleotide libraries useful for producing primers
US5451343A (en) * 1991-05-20 1995-09-19 Spectra Group Limited, Inc. Fluorone and pyronin y derivatives
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
DE69229174T2 (en) 1991-08-23 1999-09-16 Molecular Probes Inc USE OF HALOALKYL DERIVATIVES FROM REPORTER MOLECULES FOR ANALYZING METABOLIC ACTIVITY IN CELLS
US5242805A (en) * 1991-08-23 1993-09-07 Molecular Probes, Inc. Long wavelength lipophilic fluorogenic glycosidase substrates
US5576424A (en) 1991-08-23 1996-11-19 Molecular Probes, Inc. Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells
WO1994003601A2 (en) * 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
AU670108B2 (en) 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
US5274133A (en) * 1993-01-21 1993-12-28 International Flavors & Fragrances Inc. p-Methylenedioxyphenyl propionitrile derivatives, process for producing same, intermediates used in said process and organoleptic uses of said derivatives and intermediates
US5808044A (en) 1993-01-22 1998-09-15 Pharmacia Biotech Inc. Indocarbocyanine and benzindocarbocyanine phosphoramidites
US6482919B2 (en) 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5767259A (en) 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
JP3240866B2 (en) * 1995-01-19 2001-12-25 豊田工機株式会社 Power steering device
SE9500342D0 (en) * 1995-01-31 1995-01-31 Marek Kwiatkowski Novel chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
US5798276A (en) * 1995-06-07 1998-08-25 Molecular Probes, Inc. Reactive derivatives of sulforhodamine 101 with enhanced hydrolytic stability
US6008373A (en) 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US5874532A (en) * 1997-01-08 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for solution phase synthesis of oligonucleotides and peptides
US6004536A (en) 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
JP2000508709A (en) 1996-04-19 2000-07-11 アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド Squarate dyes and their use in fluorescent sequencing
FR2751430B1 (en) * 1996-07-16 1998-09-11 Aerospatiale TRANSLATION SUSPENSION AND GUIDANCE DEVICE FOR AN APPARATUS AND APPARATUS PROVIDED WITH SUCH A DEVICE
US5846737A (en) 1996-07-26 1998-12-08 Molecular Probes, Inc. Conjugates of sulforhodamine fluorophores with enhanced fluorescence
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
WO1998030575A1 (en) 1997-01-08 1998-07-16 Proligo Llc Bioconjugation of macromolecules
US5948386A (en) 1997-03-14 1999-09-07 The Curators Of The University Of Missouri Conjugate and method for forming aminomethyl phosphorus conjugates
US5773236A (en) 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
US5877310A (en) 1997-04-25 1999-03-02 Carnegie Mellon University Glycoconjugated fluorescent labeling reagents
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
ATE397013T1 (en) 1997-09-05 2008-06-15 Altus Pharmaceuticals Inc CARBOHYDRATE CROSS-LINKED GLYCOPROTEIN CRYSTALS
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6861254B1 (en) * 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US6133445A (en) 1997-12-17 2000-10-17 Carnegie Mellon University Rigidized trimethine cyanine dyes
US7427678B2 (en) 1998-01-08 2008-09-23 Sigma-Aldrich Co. Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
AU3386399A (en) 1998-04-08 1999-10-25 Ewald A. Terpetschnig Luminescent compounds
US6002003A (en) 1998-04-14 1999-12-14 Beckman Instruments, Inc. Cyanine dye activating group with improved coupling selectivity
JP3983404B2 (en) 1999-01-13 2007-09-26 本田技研工業株式会社 Radar equipped vehicle gate
US6664047B1 (en) 1999-04-30 2003-12-16 Molecular Probes, Inc. Aza-benzazolium containing cyanine dyes
ATE284433T1 (en) 1999-07-02 2004-12-15 Visen Medical Inc FLUORESCENT CYANINE LABELS WITH A SULPHAMIDO BRIDGE
EP1219626B1 (en) 1999-09-20 2005-06-01 Fuji Photo Film Co., Ltd. Compounds for fluorescence labeling
AU2001281463A1 (en) 2000-03-16 2001-09-24 The Regents Of The University Of California Chemoselective ligation
AU2001279185B2 (en) 2000-08-04 2005-07-07 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
AU2001294859A1 (en) * 2000-09-29 2002-04-08 Molecular Probes, Inc. Modified carbocyanine dyes and their conjugates
CA2425112C (en) 2000-10-06 2011-09-27 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding dna and rna
CN2445326Y (en) * 2000-10-09 2001-08-29 刘永详 Immune analysis device for assaying saccharified protein
CA2838062C (en) * 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6406926B1 (en) 2001-08-15 2002-06-18 Motorola, Inc. Method of forming a vacuum micro-electronic device
FI20011671A (en) 2001-08-20 2003-02-21 Carbion Oy Tumor-specific oligosaccharide sequences and their use
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2279755B1 (en) 2001-10-10 2014-02-26 ratiopharm GmbH Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US8323903B2 (en) * 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
DE60228492D1 (en) 2001-11-28 2008-10-02 Neose Technologies Inc REMODELING OF GLYCOPROTEINS USING ENDOGLYCANASES
CN1302006C (en) * 2001-12-14 2007-02-28 伊莱利利公司 Recombinant bovine thrombin
ES2557741T3 (en) * 2002-03-27 2016-01-28 Immunex Corporation Procedures to increase polypeptide production
ES2346646T5 (en) 2002-05-30 2018-02-15 The Scripps Research Institute Copper catalyzed ligation of azides and acetylenes
MXPA04012656A (en) * 2002-06-14 2005-08-15 Immunomedics Inc Humanized monoclonal antiboby hpam4.
JP2006509040A (en) 2002-08-23 2006-03-16 ソレックサ リミテッド Modified nucleotides
US7052843B2 (en) * 2002-10-08 2006-05-30 New York University Transcription-based assay for identification of post-translational modification and its application in proteomics
WO2004055160A2 (en) 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
WO2004063344A2 (en) 2003-01-10 2004-07-29 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE
EP2298312B1 (en) 2003-10-31 2018-09-26 Molecular Probes Inc. Fluorinated resorufin compounds and their application in detecting hydrogen peroxide
RS58420B1 (en) * 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP1687643A4 (en) 2003-11-14 2010-11-24 Irm Llc Fluorous labeling for selective processing of biologically-derived samples
US7070941B2 (en) * 2003-11-17 2006-07-04 Board Of Regents, The University Of Texas System Methods and compositions for tagging via azido substrates
WO2005051429A2 (en) † 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
WO2005075993A1 (en) 2004-02-10 2005-08-18 Korea Basic Science Institute Selective labeling agent for phosphoproteome analysis and phosphorylated site analysis
EP1730307A4 (en) 2004-03-03 2008-11-05 Univ Columbia Photocleavable fluorescent nucleotides for dna sequencing on chip constructed by site-specific coupling chemistry
JP4601060B2 (en) 2004-03-30 2010-12-22 ヤマサ醤油株式会社 Azido amino sugar nucleotides and their applications
US20080108557A1 (en) * 2004-09-29 2008-05-08 Novo Nordisk Healthcare A/G Modified Proteins
CN101068577A (en) 2004-10-07 2007-11-07 皇家飞利浦电子股份有限公司 Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy
US20060147963A1 (en) * 2004-12-30 2006-07-06 Affymetrix, Inc. Detection of polynucleotides on nucleic acid arrays using azido-modified triphosphate nucleotide analogs
MX2007013296A (en) 2005-05-02 2007-12-13 Basf Ag New labelling strategies for the sensitive detection of analytes.
WO2007120192A2 (en) 2005-10-27 2007-10-25 The President And Fellows Of Harvard College Methods and compositions for labeling nucleic acids
EP3438131B1 (en) * 2006-02-10 2022-03-16 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
ES2659816T3 (en) 2015-04-23 2018-03-19 Synaffix B.V. Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from one (1,4) -n-acetylgalactosaminyltransferase
KR20210157943A (en) 2020-06-22 2021-12-30 현대자동차주식회사 Integrated control apparatus for autonomous driving vehicle
US11820402B2 (en) 2020-07-02 2023-11-21 Qualcomm Incorporated Motion sickness detection system for autonomous vehicles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130235A1 (en) * 2003-11-18 2005-06-16 Linda Hsieh-Wilson Method and compositions for the detection of protein glycosylation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANUMULA ET AL: "Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 350, no. 1, 1 March 2006 (2006-03-01), pages 1 - 23, XP024942466, ISSN: 0003-2697, [retrieved on 20060301], DOI: 10.1016/J.AB.2005.09.037 *
LAUGHLIN S T ET AL: "Metabolic Labeling of Glycans with Azido Sugars for Visualization and Glycoproteomics", METHODS IN ENZYMOLOGY; [METHODS IN ENZYMOLOGY], ACADEMIC PRESS, US, vol. 415, 1 January 2006 (2006-01-01), pages 230 - 250, XP008100511, ISSN: 0076-6879, DOI: 10.1016/S0076-6879(06)15015-6 *
See also references of WO2007095506A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2816182C2 (en) * 2021-04-12 2024-03-26 Академиа Синика Advanced coronavirus vaccine

Also Published As

Publication number Publication date
EP3438131A1 (en) 2019-02-06
US20110207171A1 (en) 2011-08-25
US20140206848A1 (en) 2014-07-24
EP2623610B1 (en) 2015-04-29
WO2008029281A2 (en) 2008-03-13
DK1991273T3 (en) 2013-09-08
US20070249014A1 (en) 2007-10-25
EP1991273B2 (en) 2022-01-05
EP1987068A1 (en) 2008-11-05
EP3438131B1 (en) 2022-03-16
US20200216871A1 (en) 2020-07-09
EP2623986B1 (en) 2017-06-14
EP2623609B1 (en) 2017-01-04
EP2623610A2 (en) 2013-08-07
US8785212B2 (en) 2014-07-22
US20150051096A1 (en) 2015-02-19
WO2007095506A1 (en) 2007-08-23
DK1991273T4 (en) 2022-02-07
US20120301894A1 (en) 2012-11-29
EP2623986A3 (en) 2013-08-28
EP4092418A1 (en) 2022-11-23
US10676771B2 (en) 2020-06-09
JP6646537B2 (en) 2020-02-14
US20170362624A1 (en) 2017-12-21
DK3438131T3 (en) 2022-04-11
JP2018158943A (en) 2018-10-11
EP2623986A2 (en) 2013-08-07
US20170166943A1 (en) 2017-06-15
US8716033B2 (en) 2014-05-06
US20070190597A1 (en) 2007-08-16
EP1991273B1 (en) 2013-07-03
EP2623609A3 (en) 2013-08-28
JP2015044828A (en) 2015-03-12
EP1991273A4 (en) 2010-09-22
EP2623610A3 (en) 2013-09-04
US9645140B2 (en) 2017-05-09
EP2623609A2 (en) 2013-08-07
JP2016190863A (en) 2016-11-10
EP1987068B1 (en) 2018-08-08
DK1987068T3 (en) 2018-09-03
US20140377837A1 (en) 2014-12-25
EP1991273A2 (en) 2008-11-19
JP2009528988A (en) 2009-08-13
WO2008029281A3 (en) 2009-09-11
WO2007095506A8 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
EP1987068A4 (en) Oligosaccharide modification and labeling of proteins
ZA200810311B (en) Anti-NKG2A antibodies and uses thereof
HK1122196A1 (en) Protein hydrolysates and method of making
GB0711675D0 (en) Labelling of RNA
GB0620934D0 (en) Protein variants
GB0611116D0 (en) Proteins
EP2005171A4 (en) Inflammation-inhibitory serum factors and uses thereof
EP2109673A4 (en) Methods and compositions for enhanced protein expression and purification
PL2631241T3 (en) Process for generation of protein and uses thereof
IL193700A0 (en) Medicaments and proteins
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
IL194781A0 (en) New hydroxyphenyl derivatives and biological applications thereof
GB0601976D0 (en) Proteins
GB0620735D0 (en) Proteins
GB2447591B (en) Isolating both free and protein associated DNA
GB0605295D0 (en) Amino and derivatives
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
EP2034016A4 (en) Modified chondroitin synthase polypeptide and crystal thereof
EP2024516A4 (en) Perforin-2 proteins
EP1996938A4 (en) Immobilized proteins and methods and uses thereof
IL192552A0 (en) Dnt-succinate and methods of preparation thereof
GB0612443D0 (en) Protein
GB2439211B (en) Label arrangement and method of manufacture
GB2441398B (en) Labelling form and associated methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080820

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LIFE TECHNOLOGIES CORPORATION

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121128

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 17/00 20060101AFI20121122BHEP

17Q First examination report despatched

Effective date: 20141016

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LIFE TECHNOLOGIES CORPORATION

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602007055658

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07K0017000000

Ipc: C07K0001130000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/61 20170101ALI20170914BHEP

Ipc: C07K 1/13 20060101AFI20170914BHEP

INTG Intention to grant announced

Effective date: 20171005

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: GEE, KYLE R.

Inventor name: AGNEW, BRIAN

Inventor name: CORRY, SCHUYLER B.

INTG Intention to grant announced

Effective date: 20180301

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1026855

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180815

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180830

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007055658

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

RIC2 Information provided on ipc code assigned after grant

Ipc: C07K 1/13 20060101AFI20170914BHEP

Ipc: A61K 47/61 20170101ALI20170914BHEP

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1026855

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181208

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181108

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181109

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

RIC2 Information provided on ipc code assigned after grant

Ipc: C07K 1/13 20060101AFI20170914BHEP

Ipc: A61K 47/61 20170101ALI20170914BHEP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007055658

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190212

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070212

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230520

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240226

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240206

Year of fee payment: 18

Ref country code: GB

Payment date: 20240208

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240219

Year of fee payment: 18

Ref country code: FR

Payment date: 20240228

Year of fee payment: 18

Ref country code: DK

Payment date: 20240102

Year of fee payment: 18